Recent Advances in the Treatment of Alopecia Areata : Episode 3

Opinion

Video

April 3, 2023

Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

Author(s):

Raj Chovatiya, MD, PhD,George Han, MD, PhD

The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.

EP: 1.Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

EP: 2.JAK Inhibitor Baricitinib for Treatment of Alopecia Areata

EP: 3.Analyzing Phase 3 Clinical Trial Data of Baricitinib in Alopecia Areata

EP: 4.Novel Mechanisms of Action for Treatment of Alopecia Areata

EP: 5.Physician and Patient Communication for the Management of Alopecia Areata

EP: 6.The Pathophysiology of Alopecia Areata

EP: 7.The Benefits of Early Diagnosis of Alopecia Areata

EP: 8.Patient Factors and Other Considerations for Treatment Selection

EP: 9.Treatment Options for Alopecia Areata

EP: 10.Review of FDA Approved JAK Inhibitors for Alopecia Areata

EP: 11.JAK Inhibition in the Treatment of Alopecia Areata

EP: 12.Assessing Risk and Safety of JAK Inhibitors

EP: 13.Real-World Clinical Experience With JAK Inhibitors

Related Videos

Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa

Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD

Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD

2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.